Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 醫學系
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/525206
Title: Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study
Authors: Yeh T.-C.
Liang D.-C.
Hou J.-Y.
Jaing T.-H.
Lin D.-T.
Yang C.-P.
Peng C.-T.
Hung I.-J.
Lin K.-H.
Hsiao C.-C.
SHIANN-TANG JOU 
Chiou S.-S.
Chen J.-S.
Wang S.-C.
Chang T.-K.
Wu K.-H.
Sheen J.-M.
Yen H.-J.
Chen S.-H.
MENG-YAO LU 
MENG-JU LI 
Chang T.-T.
Huang T.-H.
Chang Y.-H.
Chen S.-H.
YUNG-LI YANG 
HSIU-HAO CHANG 
Chen B.-W.
Lin P.-C.
Cheng C.-N.
Chao Y.-H.
Yang S.-H.
Chao Y.-M.Y.
Liu H.-C.
Issue Date: 2018
Publisher: John Wiley and Sons Inc.
Journal Volume: 124
Journal Issue: 23
Start page/Pages: 4538-4547
Source: Cancer
Abstract: 
Background: To eliminate cranial irradiation (CrRT)–related sequelae and to minimize the adverse impact of traumatic lumbar puncture (TLP) with blasts, the Taiwan Pediatric Oncology Group (TPOG) introduced a modified central nervous system (CNS)–directed regimen characterized by delayed triple intrathecal therapy (TIT) and the omission of CrRT for all children with newly diagnosed acute lymphoblastic leukemia (ALL). Methods: This study compared the treatment outcomes of patients overall and patients with a non–CNS-1 status (CNS-2, CNS-3, or TLP with blasts) in 2 treatment eras, one before and another after the revision of the TPOG-ALL-2002 protocol by the introduction of the modification (era 1 [2002-2008] with CrRT and era 2 [2009-2012] with delayed first TIT and no CrRT). Results: There were no statistically significant differences in major outcomes between the 903 patients treated in era 1 and the 444 patients treated in era 2: the 5-year event-free survival (EFS) rates were 75.7% ± 1.4% and 72.1% ± 2.4%, respectively (P =.260), and the cumulative risks of isolated CNS relapse were 4.0% ± 0.7% and 4.1% ± 1.0%, respectively (P =.960). There were also no differences between non–CNS-1 patients treated in era 1 (n = 76) and era 2 (n =28): the 5-year EFS rates were 52.3% ± 5.8% and 62.9% ± 9.4%, respectively (P =.199), and the cumulative risks of isolated CNS relapse were 6.3% ± 3.1% and 3.6% ± 3.5%, respectively (P =.639). Notably, TLP with blasts was completely eliminated after the first TIT was delayed in era 2. Conclusions: The delay of the first TIT until the clearance of circulating blasts and the total omission of CrRT did not compromise survival or CNS control in patients with childhood ALL, including those with a non–CNS-1 status. ? 2018 American Cancer Society
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054690610&doi=10.1002%2fcncr.31758&partnerID=40&md5=8e306ec8733f2dcab6bea2c2c9ee99cf
https://scholars.lib.ntu.edu.tw/handle/123456789/525206
ISSN: 0008-543X
DOI: 10.1002/cncr.31758
SDG/Keyword: acute lymphoblastic leukemia; Article; cancer recurrence; cancer survival; child; childhood leukemia; comparative study; event free survival; female; follow up; human; major clinical study; male; priority journal; risk factor; skull irradiation; therapy delay; treatment outcome; acute lymphoblastic leukemia; adolescent; adverse event; central nervous system tumor; clinical trial; infant; intraspinal drug administration; newborn; preschool child; procedures; skull irradiation; survival analysis; time to treatment; antineoplastic agent; Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Cranial Irradiation; Female; Humans; Infant; Infant, Newborn; Injections, Spinal; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Time-to-Treatment; Treatment Outcome
[SDGs]SDG3
Appears in Collections:醫學系

Show full item record

SCOPUSTM   
Citations

15
checked on Mar 27, 2023

WEB OF SCIENCETM
Citations

16
checked on Mar 19, 2023

Page view(s)

24
checked on Mar 27, 2023

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback